GLP-1 drugs increase rare ‘eye stroke’ linked to vision loss, hundreds of lawsuits allege

Live updates

1. 21d ago

   GLP-1 drugs linked to rare 'eye stroke' and vision loss

   Hundreds of lawsuits allege GLP-1 medications like Ozempic and Wegovy cause nonarteritic anterior ischemic optic neuropathy (NAION), a condition restricting blood flow to the optic nerve, potentially resulting in permanent vision loss. A Rutgers-led study and European regulators confirm a small increase in risk, describing the occurrence as very rare. Patients report sudden blindness, with data suggesting a relative increase in NAION cases among adults with type 2 diabetes using semaglutide.

   Why it matters

   The lawsuits center on the failure of pharmaceutical companies to warn users of these risks. GLP-1 medications are widely used for type 2 diabetes and weight loss. NAION can cause sudden and permanent vision loss. The condition's rarity and the drugs' benefits complicate the risk-benefit analysis.

   What is confirmed

   • GLP-1 medications can lead to long-term side effects for some people.
   • GLP-1 drugs may influence mood, reward processing, cognition, reproductive health, and neurodegenerative diseases.
   • A Rutgers-led study and European regulators confirm a small increase in NAION risk associated with GLP-1 medications.

   Still unconfirmed

   • Some patients report sudden blindness after using GLP-1 medications.

   What to watch next

   • Further studies on the incidence of NAION among GLP-1 medication users
   • Regulatory updates on warnings and labels for GLP-1 medications
   • Developments in the ongoing lawsuits against pharmaceutical companies
   Sources used for this update (2)

   1. www.healthline.com — What to Know About GLP-1 Long-term Side Effects - Healthline
   2. www.news-medical.net — How GLP-1 Drugs Affect the Brain Beyond Weight Loss
   confidence 85%
2. 25d ago

   GLP-1 Drugs Linked to Rare Eye Stroke Risk Amid Growing Litigation

   Hundreds of lawsuits now target makers of GLP-1 medications like Ozempic and Wegovy, alleging the drugs cause nonarteritic anterior ischemic optic neuropathy (NAION). This condition restricts blood flow to the optic nerve and can result in permanent vision loss. While a Rutgers-led study and European regulators confirm a small increase in risk, they describe the occurrence as very rare. Some patients report sudden blindness, while data suggests a relative increase in NAION cases among adults with type 2 diabetes using semaglutide. Legal claims center on the failure of pharmaceutical companies to warn users of these risks.

   Why it matters

   NAION is a rare condition that can cause sudden blindness or permanent blind spots. Because millions of people now use these drugs for weight loss and diabetes, even a low absolute risk can affect a significant number of patients. The debate focuses on whether the observed association proves direct causation.

   What is confirmed

   • European regulators designated NAION as a very rare side effect of GLP-1 medicines in June 2025.
   • A meta-analysis in Ophthalmology linked semaglutide to non-arteritic anterior ischaemic optic neuropathy.
   • Rutgers researchers found a modest increase in ischemic optic neuropathy linked to GLP-1 drugs.
   • Pooled data for adults with type 2 diabetes showed 26.7 NAION cases per 100,000 person-years on semaglutide compared to 18.9 without it.
   • Hundreds of lawsuits allege that drugmakers failed to warn users about the risk of permanent vision loss.

   Still unconfirmed

   • Todd Engel claims Ozempic caused his total vision loss in both eyes.
   • Diane Wirth reports waking up with much of the vision in her right eye gone after taking Wegovy.
   • The lead author of the Rutgers study states the data does not establish causation.

   What to watch next

   • Court rulings on whether drugmakers provided adequate warnings for NAION.
   • Further large-scale studies to establish a direct causal link between GLP-1s and eye strokes.
   Sources used for this update (9)

   1. www.dailymail.com — Ozempic maker hit with lawsuits over 'eye stroke' condition
   2. www.yahoo.com — Hundreds Sue GLP-1 Drugmakers Over Vision Loss ... - Yahoo
   3. www.sciencedaily.com — Ozempic and Wegovy linked to rare risk of sudden vision loss
   4. www.foxnews.com — Ozempic lawsuit claims drug caused total vision loss in both ...
   5. ushealthdigest.com — Semaglutide and Rare Vision Loss: What NAION Data Show
   6. www.thepeptidenewsroom.com — GLP-1 Drugs Linked to Rare Sudden Vision Loss, But Absolute ...
   7. www.robertkinglawfirm.com — Wegovy Vision Loss Lawsuit [2026 Update] - King Law
   8. welltica.com — Taking Ozempic or Wegovy? Researchers have flagged a rare but ...
   9. www.prnewswire.com — Attorney Tracy Paulsen Brings Focused Experience to Growing ...
   confidence 90%
3. 30d ago

   GLP-1 Drugs Linked to Faster Vision Loss in Second Eye

   Patients taking GLP-1 medications who experience a rare optic nerve stroke in both eyes suffer damage to the second eye sooner than other patients. This finding comes as hundreds of federal lawsuits continue to target pharmaceutical makers over popular blockbusters including Ozempic, Wegovy, and Mounjaro. Plaintiffs allege these companies failed to provide adequate warnings regarding the risk of nonarteritic anterior ischemic optic neuropathy, which causes permanent vision loss. Meanwhile, over one thousand reports of eye damage linked to these drugs have been filed with federal regulators since 2024, though researchers and observers note that the exact frequency and direct causation remain unclear amid widespread use.

   Why it matters

   The rising volume of litigation and regulatory filings compounds medical scrutiny around blockbuster diabetes and weight-loss drugs. Researchers presented the findings regarding accelerated bilateral timeline damage at a Boston aging meeting. While associations between the medications and the rare eye condition have been established, scientific consensus on direct causation has not yet been reached.

   What is confirmed

   • Among patients who suffered a rare optic nerve stroke in both eyes, those taking GLP-1 drugs saw the second eye affected sooner.
   • Hundreds of federal lawsuits continue to target pharmaceutical makers, alleging inadequate warnings regarding nonarteritic anterior ischemic optic neuropathy.
   • Over 1,000 reports of eye damage linked to GLP-1 drugs have been filed with the FDA since 2024.

   Still unconfirmed

   • GLP-1 drugs can directly cause serious harm such as permanent vision loss, according to ongoing lawsuits.

   What to watch next

   • Determining whether definitive causation can be established between GLP-1 drugs and nonarteritic anterior ischemic optic neuropathy.
   • Progress and rulings in the federal lawsuits targeting pharmaceutical makers of drugs like Ozempic, Wegovy, and Mounjaro.
   Sources used for this update (2)

   1. www.aao.org — GLP-1 Drugs Linked to Faster Vision Loss in the Second Eye ...
   2. rocketnews.com — Ongoing lawsuits allege GLP-1s can cause serious harm. But we ...
   confidence 100%
4. 35d ago

   New Study Links GLP-1 Drugs to Faster Second-Eye Vision Loss

   Patients taking GLP-1 receptor agonists who experience a rare optic nerve stroke in both eyes suffer damage to the second eye sooner than others. A recent study presented at a Boston aging meeting highlights this accelerated timeline, though researchers caution that an association has been established rather than direct causation. This finding compounds existing legal and medical scrutiny surrounding popular blockbusters like Ozempic, Wegovy, and Mounjaro. Hundreds of federal lawsuits continue to target pharmaceutical makers, alleging inadequate warnings regarding the risk of nonarteritic anterior ischemic optic neuropathy, a permanent form of vision loss.

   Why it matters

   The legal battle centers on whether pharmaceutical companies failed to warn patients adequately about nonarteritic anterior ischemic optic neuropathy, also known as NAION. While international regulators in Europe, the UK, and Australia have taken action regarding the condition, U.S. product labels do not feature a formal warning. Experts and legal counsel, including New Jersey co-lead counsel Ellen Relkin, are actively debating the evidence and counseling patients on risk factors and symptoms.

   What is confirmed

   • More than 200 federal lawsuits target the makers of popular GLP-1 receptor agonist medications over a rare form of permanent vision loss known as NAION.
   • Among patients who suffered a rare optic nerve stroke in both eyes, those taking GLP-1 drugs saw the second eye affected sooner.
   • International regulators in Europe, the UK, and Australia have taken action, but U.S. product labels still lack a formal warning regarding the condition.

   Still unconfirmed

   • For people with diabetes, GLP-1 drugs may be linked to lower odds of a leading cause of blindness once researchers account for patient records.

   What to watch next

   • Decisions by U.S. regulators regarding whether to add formal warnings for NAION to product labels
   • Further developments and trial proceedings in the federal lawsuits against GLP-1 manufacturers
   Sources used for this update (8)

   1. www.newswise.com — GLP-1 Drugs Linked to Faster Vision Loss in the Second Eye, New Study Finds
   2. www.newswise.com — For People With Diabetes, GLP-1 Drugs May Be Linked to Lower Odds of a Leading Cause of Blindness
   3. www.drugwatch.com — I Interviewed One of the Lead Attorneys in the Ozempic Vision ...
   4. www.medscape.com — GLP-1s and NAION: Do Patients Need a Warning? - Medscape
   5. lawsuitinformer.com — Ozempic Vision Loss Lawsuits: NAION Explained
   6. www.drugwatch.com — Ozempic Vision Loss (NAION): Symptoms, Causes and Risks
   7. www.medicaldaily.com — Second-Eye Optic Nerve Strokes Came Sooner in GLP-1 Users ...
   8. www.technologyreview.com — We’re still figuring out the side effects of GLP-1 weight-loss drugs
   confidence 90%
5. 39d ago

   GLP-1 Drugs Face Over 200 Lawsuits Over Rare Vision Loss

   More than 200 federal lawsuits target the makers of popular GLP-1 receptor agonist medications, alleging the treatments cause a rare and permanent form of vision loss known as nonarteritic anterior ischemic optic neuropathy, or NAION. Plaintiffs claim that pharmaceutical companies failed to provide adequate warnings about the eye stroke risk associated with blockbusters like Ozempic, Wegovy, and Mounjaro. Manufacturers are disputing these claims. While international regulators in Europe, the UK, and Australia have taken action, U.S. product labels still lack a formal warning regarding the condition.

   Why it matters

   GLP-1 medications are widely prescribed injections that help manage Type 2 diabetes and obesity, with clinical trials also indicating potential benefits for heart-care. However, accumulating legal actions and safety signals have brought scrutiny to unexpected side effects beyond the well-documented gastrointestinal issues. The Food and Drug Administration previously flagged NAION as a safety signal in March 2025, but regulatory actions in the United States have lagged behind international authorities.

   What is confirmed

   • Over 200 federal lawsuits allege GLP-1 drugs like Ozempic and Mounjaro caused NAION, a rare permanent vision loss condition, with manufacturers disputing the claims.
   • The FDA listed NAION as a possible GLP-1 safety signal in March 2025, yet U.S. labels still lack a warning, while Europe, the UK, and Australia have acted.
   • Edward Gillen injected Ozempic believing that he was doing something to promote his health when, in fact, it had the opposite effect.

   Still unconfirmed

   • Plaintiffs who suffered permanent blindness over Memorial Day weekend may qualify for compensation through pending pharmaceutical litigation.

   What to watch next

   • Decisions by U.S. regulators regarding whether to update product labels with a formal NAION warning.
   • Progress and consolidation of the more than 200 federal lawsuits targeting GLP-1 manufacturers.
   Sources used for this update (17)

   1. med.stanford.edu — GLP-1s 101: What the science says about weight loss, side effects, safety
   2. www.boston.com — Mass. man alleges in lawsuit that GLP-1 caused permanent ...
   3. my.clevelandclinic.org — GLP-1 Agonists: What They Are, How They Work & Side Effects
   4. www.webmd.com — A Guide to GLPs-1s for Weight Loss - WebMD
   5. nypost.com — Dad says he went permanently blind — in lawsuit against ...
   6. www.lanierlawfirm.com — NAION Ozempic GLP-1 Drugs Lawsuit: September 2026 Update
   7. www.yahoo.com — Ozempic, Wegovy users sue over rare, permanent blindness - Yahoo
   8. www.drugwatch.com — Ozempic Lawsuit: September 2026 Blindness and Gastroparesis ...
   9. www.medicaldaily.com — FDA Flagged GLP-1 Vision Loss Signal in 2025, but U.S ...
   10. timesofindia.indiatimes.com — GLP-1 drugs: From weight loss wonder to potential heart-care tool | Bengaluru News
   11. weightlossproviderguide.com — GLP-3 Retatrutide: Results, Side Effects & Trials
   12. en.wikipedia.org — Glucagon-like peptide-1 - Wikipedia
   confidence 92%
6. 45d ago

   GLP-1 drugs linked to rare 'eye stroke' and vision loss in hundreds of lawsuits

   Hundreds of lawsuits allege that GLP-1 receptor agonists, used for weight loss and diabetes treatment, increase the risk of a rare form of vision loss called nonarteritic anterior ischemic optic neuropathy (NAION). Plaintiffs claim they were not adequately warned about this potential risk. The scientific evidence is still evolving and not completely consistent. GLP-1 drugs, including Ozempic, Wegovy, and Mounjaro, are at the center of the legal and medical debate.

   Why it matters

   The lawsuits have sparked a growing legal and medical debate over the safety of GLP-1-based medicines. NAION is a rare condition that can cause sudden and permanent vision loss. The condition has been linked to various factors, including diabetes, high blood pressure, and certain medications. The scrutiny on GLP-1 drugs comes as they become increasingly popular for weight loss and diabetes treatment.

   What is confirmed

   • Hundreds of consumers are suing GLP-1 receptor agonist manufacturers, alleging the medications may increase the risk of NAION.
   • The lawsuits claim that patients were not adequately warned about the potential risk of NAION.
   • GLP-1 drugs, including Ozempic, Wegovy, and Mounjaro, are linked to NAION in the lawsuits.

   Still unconfirmed

   • Proving a direct link between GLP-1 drugs and NAION may be difficult without FDA support.

   What to watch next

   • Further studies on the link between GLP-1 drugs and NAION
   • FDA review of GLP-1 drug safety
   • Developments in the ongoing lawsuits
   Sources used for this update (14)

   1. USA Today — Are GLP-1s causing blindness? What we know about rare cases
   2. ABC News - Breaking News, Latest News and Videos — What GLP-1 users should know about the potential risk of a rare type of vision loss
   3. Fox News — Popular weight-loss drugs face numerous lawsuits over rare ‘eye stroke’ linked to vision loss
   4. Al Jazeera — Can GLP-1 drugs like Ozempic cause vision loss? What we know about the risk
   5. nypost.com — GLP-1 drugs increase rare ‘eye stroke’ linked to vision loss, hundreds of lawsuits allege
   6. New York Post — GLP-1 drugs increase rare ‘eye stroke’ linked to vision loss, hundreds of lawsuits allege
   7. www.aol.com — Doctor warns of risk of 'eye stroke' possibly linked to GLP-1 weight loss drugs
   8. ticklethewire.com — Rare Prosecution of ICE Officer Raises Questions About DOJ Shooting Investigations
   9. economictimes.indiatimes.com — GLP-1 vision loss lawsuit: GLP-1 users are suing over vision ...
   10. onedaymd.aestheticsadvisor.com — Patients Sue GLP-1 Drugmakers Over Risk of Sudden Vision Loss ...
   11. www.medicaldaily.com — Hundreds of Lawsuits Allege Ozempic and Other GLP-1 Drugs Caused Sudden Vision Loss, but Absolute Risk Ap....
   12. www.yahoo.com — Ozempic Vision Loss Lawsuits Allege Permanent Eye Damage - Yahoo
   confidence 85%